Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules

Patent metadata

Field	Value
Publication number	US-10532099-B2
Application number	US-201715786847-A
Country	US
Kind code	B2
Filing date	Oct 18, 2017
Priority date	Oct 18, 2016
Publication date	Jan 14, 2020
Grant date	Jan 14, 2020

Abstract

Disclosed are CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV. Immunization with the disclosed CMV vectors allow selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.

First claim

The invention claimed is:

1. A cytomegalovirus (CMV) vector comprising:
(a) a first nucleic acid sequence that encodes at least one heterologous antigen; and
(b) a second nucleic acid sequence comprising a first heterologous microRNA recognition element (MRE) operably linked to a CMV gene that is essential or augmenting for CMV growth, wherein the MRE is complementary to a microRNA that is expressed by a cell of endothelial lineage;
wherein the vector does not express an active UL128 protein or ortholog thereof; does not express an active UL130 protein or ortholog thereof; does not express an active UL146 or ortholog thereof; and does not express an active UL147 protein or ortholog thereof; and wherein the microRNA is miR-126-3p, miR-130a, miR-210, miR-221/222, miR-378, miR-296, or miR-328.

2. The CMV vector of claim 1 , wherein the microRNA is miR-126-3p.

3. The CMV vector of claim 2 , wherein the gene that is essential or augmenting for CMV growth is UL122 (IE2) or UL79.

4. The CMV vector of claim 1 , wherein the at least one heterologous antigen comprises a pathogen-specific antigen, a tumor antigen, a tissue-specific antigen, or a host self-antigen.

5. The CMV vector of claim 4 , wherein the host self-antigen is an antigen derived from the variable region of a T cell receptor (TCR) or an antigen derived from the variable region of a B cell receptor.

6. The CMV vector of claim 4 , wherein the pathogen specific antigen is derived from a pathogen selected from the group consisting of: human immunodeficiency virus, simian immunodeficiency virus, herpes simplex virus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.

7. The CMV vector of claim 4 , wherein the tumor antigen is related to a cancer selected from the group consisting of: acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, malignant melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, colon cancer, renal cell carcinoma (RCC), and germ cell tumors.

8. The CMV vector of claim 1 , wherein the CMV vector does not express an active UL82 (pp71) protein, or an ortholog thereof.

9. The CMV vector of claim 1 , wherein the CMV vector does not express an active US11 protein, or an ortholog thereof.

10. The CMV vector of claim 1 , wherein the CMV vector does not express an active UL82 (pp71) protein or an active US11 protein, or orthologs thereof.

11. The CMV vector of claim 1 , wherein the CMV vector is a human CMV vector (HCMV), a cynomolgus CMV (CyCMV) vector, or a rhesus CMV (RhCMV) vector.

12. A method of generating an immune response in a subject to at least one heterologous antigen, the method comprising:
administering to the subject the CMV vector of claim 1 in an amount effective to elicit a CD8+ T cell response to the at least one heterologous antigen.

13. The method of claim 12 , wherein at least 10% of the CD8+ T cells elicited by the CMV vector are restricted by MHC-E or an ortholog thereof.

14. The method of claim 13 , wherein at least 20% of the CD8+ T cells elicited by the CMV vector are restricted by MHC-E or an ortholog thereof.

15. The method of claim 12 , wherein fewer than 10% of the CD8+ T cells elicited by the CMV vector are restricted by MHC-class Ia or an ortholog thereof.

16. The method of claim 12 , wherein some of the CD8+ T cells restricted by MHC-E recognize peptides shared by at least 90% of other subjects immunized with the vector.

17. The method of claim 12 , further comprising administering to the subject a second CMV vector comprising a nucleic acid sequence that encodes at least one heterologous antigen.

18. The method of claim 17 , wherein the second CMV vector expresses one or more active proteins selected from the group consisting of: UL128, or an ortholog thereof; UL129, or an ortholog thereof; UL146, or an ortholog thereof; and UL147, or an ortholog thereof.

19. The method of claim 17 , wherein the at least one heterologous antigen of the first CMV vector and the second CMV vector are the same antigen.

20. The method of claim 17 , wherein the second CMV vector is administered before, concurrently with, or after the first CMV vector.

21. The method of claim 12 , wherein the subject has been previously exposed to CMV.

22. The method of claim 12 , wherein the subject is a human or nonhuman primate.

23. The method of claim 12 , wherein administering the CMV vector comprises subcutaneous, intravenous, intramuscular, intraperitoneal, or oral administration of the CMV vector.

24. The method of claim 13 , further comprising identifying a CD8+ TCR from the CD8+ T cells elicited by the CMV vector, wherein the CD8+ TCR recognizes a MHC-E/heterologous antigen-derived peptide complex.

25. The method of claim 24 , wherein the CD8+ TCR is identified by DNA or RNA sequencing.

26. A cytomegalovirus (CMV) vector comprising:
(a) a first nucleic acid sequence that encodes at least one heterologous antigen;
(b) a second nucleic acid sequence comprising a first heterologous microRNA recognition element (MRE) operably linked to a CMV gene that is essential or augmenting for CMV growth, wherein the MRE is complementary to a first microRNA that is expressed by a cell of endothelial lineage; and
(c) a third nucleic acid sequence comprising a second heterologous MRE operably linked to a CMV gene that is essential or augmenting for CMV growth, wherein the second MRE is complementary to a second microRNA that is expressed by a cell of myeloid lineage;
wherein the vector does not express an active UL128 protein or ortholog thereof; does not express an active UL130 protein or ortholog thereof; does not express an active UL146 protein or ortholog thereof; and does not express an active UL147 protein or ortholog thereof; wherein the first microRNA is miR-126-3p, miR-130a, miR-210, miR-221/222, miR-378, miR-296, or miR-328: and wherein the second microRNA is miR-142-3p, miR-223, miR-27a, miR-652, miR-155, miR-146a, miR-132, miR-21, or miR-125.

27. The CMV vector of claim 26 , wherein the first microRNA is miR-126-3p.

28. The CMV vector of claim 27 , wherein the CMV gene that is essential or augmenting for CMV growth is UL122 (IE2) or UL79.

29. The CMV vector of claim 26 , wherein the second microRNA is miR-142-3p.

30. The CMV vector of claim 26 , wherein the at least one heterologous antigen comprises a pathogen-specific antigen, a tumor antigen, a tissue-specific antigen, or a host self-antigen.

31. The CMV vector of claim 30 , wherein the host self-antigen is an antigen derived from the variable region of a T cell receptor (TCR) or an antigen derived from the variable region of a B cell receptor.

32. The CMV vector of claim 30 , wherein the pathogen-specific antigen is derived from a pathogen selected from the group consisting of: human immunodeficiency virus, simian immunodeficiency virus, herpes simplex virus type 1, herpes simplex virus type 2, hepatitis B virus, hepatitis C virus, papillomavirus, Plasmodium parasites, and Mycobacterium tuberculosis.

33. The CMV vector of claim 30 , wherein the tumor antigen is related to

Assignees

• Univ Oregon Health & Science

Inventors

• Picker Louis
• Hansen Scott
• Frueh Klaus
• Malouli Daniel
• Nelson Jay
• Sacha Jonah
• Hancock Meaghan

Classifications

• C12N2710/16171

  Demonstrated in vivo effect · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• C07K14/005

  from viruses · CPC title